Abstract 1028
Background
IMDC classifies patients (pt) with mRCC in favorable, intermediate or poor-risk (FR, IR, PR). IR pt having 1 vs 2 unfavorable factors (IR1 vs IR2) treated with sunitinib in clinical trials, have different outcomes (Rini, ASCO 2017). Outcomes are also better foreligible vs ineligible pt for clinical trials (E vs I, Arranz, ESMO 2017).We compare IR1 vs IR2 in I vs E pt receiving 1stPz, and validate the IMDC-modified models.
Methods
SPAZO2 (NCT03091465) retrospectively analyzed the real-world effectiveness of 1stPz in mRCC in 530 pt from 50 centers in Spain. Data were externally monitored. Median follow-up was 39 months (mo). No pt received Nivo or Cabo as 2nd-line.
Results
Among the 323 pt classified as IR1 (53%) or IR2 (47%), we found differences (p < 0.05) in mean age (64 vs 68 y), prior nephrectomy (80 vs 65%), ECOG 0-1 (98 vs 93%), Hb 954PORR (%) Median PFS (mo) Median OS (mo) E I E I E I FR 63 47 23.5 13.5 42.3 29.0 IR1 45.9 37.5 11.0 14.7 26.4 24.1 IR2 21.6 14.3 10.0 7.9 18.0 14.8 PR 33 16 7.5 5.2 14.2 5.9
Conclusions
In our real-world study before Nivo/Cabo approval for 2nd-line, pt with IR1 had statistically significant better ORR and longer OS than IR2. The discrimination power of the IMDC model can be improved by subclassifying patients of the intermediate group and eligibility for clinical trials.
Clinical trial identification
NCT03091465.
Editorial acknowledgement
Legal entity responsible for the study
SOGUG: Spanish Oncology Genito-Urinary Group.
Funding
Novartis.
Disclosure
B. P. Valderrama: Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self): Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Sanofi; Advisory / Consultancy: MSD Oncology; Travel / Accommodation / Expenses: Janssen-Cilag; Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: EUSA Pharma. A. Rodriguez-Vida: Honoraria (self), Advisory / Consultancy: MSD Oncology; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers-Squibb; Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy: Janssen-Cilag; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self): AstraZeneca; Honoraria (self): Sanofi-Aventis; Research grant / Funding (institution): Takeda. A. González del Alba: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi-Aventis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Meyer-Squibb; Travel / Accommodation / Expenses: MSD Oncology; Advisory / Consultancy: Bayer; Advisory / Consultancy: Eisai; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pierre-Fabre; Advisory / Consultancy: EUSA Pharma. M.J. Mendez Vidal: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Advisory / Consultancy: Bayer Healthcare; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Sanofi-Aventis; Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Travel / Accommodation / Expenses: Bristol-Meyer-Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer. S. Vazquez Estevez: Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Bristol-Meyer-Squibb; Honoraria (self), Advisory / Consultancy: Boehringer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy: Novartis; Advisory / Consultancy: EUSA Pharma; Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self): Lilly. O. Fernández Calvo: Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bristol-Meyer-Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Sanofi-Aventis. C. Suarez Rodriguez: Honoraria (self), Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers-Squibb; Advisory / Consultancy: EUSA Pharma; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (institution): Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Sanofi-Aventis; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Research grant / Funding (institution): AB Science; Research grant / Funding (institution): Aragon Pharmaceuticals; Research grant / Funding (institution): Arog Pharmaceuticals INC; Research grant / Funding (institution): Bayer AG; Research grant / Funding (institution): Aveo Pharmaceuticals INC; Research grant / Funding (institution): Blueprint Medicines Corporation; Research grant / Funding (institution): BN Immunopharmaceutics INC; Research grant / Funding (institution): Boehringer Ingelheim España S.A.; Research grant / Funding (institution): Bristol-Myers-Squibb International Corporation; Research grant / Funding (institution): Clovis Oncology INC; Research grant / Funding (institution): Cougar Biotechnology INC; Research grant / Funding (institution): Deciphera Pharmaceuticals LLC; Research grant / Funding (institution): Exelixis INC; Research grant / Funding (institution): Hoffmann-La Roche LTD; Research grant / Funding (institution): Genentech INC; Research grant / Funding (institution): GlaxoSmithKline, S.A; Research grant / Funding (institution): Incyte Corporation; Research grant / Funding (institution): Janssen-Cilag International NV; Research grant / Funding (institution): Karyopharm Therapeutics INC; Research grant / Funding (institution): Laboratoires Leurquin Mediolanum SAS; Research grant / Funding (institution): Lilly S.A.; Research grant / Funding (institution): Medimmune; Research grant / Funding (institution): Millennium Pharmaceuticals INC; Research grant / Funding (institution): Nanobiotix S.A.; Research grant / Funding (institution): Novartis Farmacéutica S.A.; Research grant / Funding (institution): Pfizer SLU; Research grant / Funding (institution): Teva Pharma SLU; Research grant / Funding (institution): Puma Biotechnology INC; Research grant / Funding (institution): Sanofi-Aventis S.A.; Research grant / Funding (institution): SFJ Pharma LTD.II. E. Gallardo Diaz: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi-Aventis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Astellas-Pharma; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ipsen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Eisai; Advisory / Consultancy: EUSA Pharma; Advisory / Consultancy: Bristol-Myers-Squibb; Honoraria (self), Advisory / Consultancy: Rovi; Travel / Accommodation / Expenses: Pierre-Fabre; Honoraria (self), Advisory / Consultancy: Daiichi; Honoraria (self), Advisory / Consultancy: Sankyo; Advisory / Consultancy: Techdow; Advisory / Consultancy: Leo Pharma; Advisory / Consultancy: Menarini; Travel / Accommodation / Expenses: Ferrer; Travel / Accommodation / Expenses: GSK. J.A. Arranz Arija: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD Oncology; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Janssen-Cilag; Honoraria (self), Advisory / Consultancy: EUSA Pharma; Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers-Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Bayer; Advisory / Consultancy: Ipsen; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pierre-Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract